Curated News
By: NewsRamp Editorial Staff
September 23, 2024

AGC Biologics Partners with CompleCure to Develop Advanced Anti-Cancer Therapeutic Using Pioneering AMDC Technology

Reddit Discuss on RedditDiscuss on LinkedIn LinkedInDiscuss on Substack SubstackDiscuss on Telegram TelegramView History of this news story on GitHub Github
Source News Release

TLDR

  • AGC Biologics partners with CompleCure to develop a groundbreaking anti-cancer therapeutic, giving a competitive advantage in the cancer treatment market.
  • AGC Biologics' Chiba facility is using advanced technologies in microbial expression to develop a complex tetrameric protein component for the new anti-cancer therapeutic.
  • The collaboration between AGC Biologics and CompleCure has the potential to revolutionize breast cancer treatment, significantly improving patient outcomes and quality of life.
  • The new AMDC technology represents a significant evolution in cancer treatment, offering a promising new approach to targeting and destroying cancer cells.

Impact - Why it Matters

This news matters because it represents a significant advancement in cancer treatment, with the potential to revolutionize breast cancer therapy and improve patient outcomes. The collaboration between AGC Biologics and CompleCure could lead to the commercialization of a promising new treatment, ultimately contributing to the improvement of quality of life for cancer patients worldwide.

Summary

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization, has entered into a strategic service agreement with CompleCure to develop a novel anti-cancer therapeutic using Antibody Mimetics Drug Conjugate (AMDC) technology. AGC Biologics will focus on developing the manufacturing process for the protein component of the therapeutic at its facility in Chiba, Japan. CompleCure's goal is to revolutionize breast cancer treatment, with the new therapeutic aiming to achieve complete remission with minimal side effects. The collaboration between AGC Biologics and CompleCure represents a significant milestone in the path toward the commercialization of AMDC-based therapeutics, ultimately contributing to the improvement of quality of life for cancer patients worldwide.

Source Statement

This curated news summary relied on this press release disributed by News Direct. Read the source press release here, AGC Biologics Partners with CompleCure to Develop Advanced Anti-Cancer Therapeutic Using Pioneering AMDC Technology

blockchain registration record for the source press release.